ABSTRACT
OBJECTIVE: The effect of Alstonia boonei fractions on glucose homeostasis was investigated via in vitro enzyme inhibition activity, ex vivo glucose uptake assay, and in vivo methods in diabetic rats. METHODOLOGY: A. boonei fractions were subjected to in vitro α-glucosidase inhibitory assay and then ex vivo glucose uptake activity. The butanol fraction of the leaves (ABBF) was picked for the in vivo assay since it showed more activity in the initial tests conducted. ABBF was administrated via oral dosing to six-weeks old fructose-fed STZ-induced type 2 diabetic rats over a 5-week experimental period. RESULTS: ABBF treatment at a low dose of 150 mg/kg bw, significantly (p < .05) reduced blood glucose level, enhanced oral glucose tolerance ability, restored insulin secretion and hepatic glycogen synthesis as well as promoted islet regeneration than the high dose (300 mg/kg bw). CONCLUSION: These results suggest that ABBF could be exploited as a therapeutic potential for treating T2D.
Subject(s)
Alstonia , Diabetes Mellitus, Experimental , Rats , Animals , Hypoglycemic Agents/adverse effects , Butanols/adverse effects , Plant Extracts/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/chemically induced , 1-Butanol/adverse effects , Oxidative Stress , Glucose/adverse effects , Plant Leaves , Blood GlucoseABSTRACT
Idiopathic leukoderma is a skin disorder characterized by patchy loss of skin pigmentation due to melanocyte dysfunction or deficiency. Rhododendrol (RD) was approved as a cosmetic ingredient in Japan in 2008. However, it was shown to induce leukoderma in approximately 20,000 customers. The prediction of cytotoxicity, especially to melanocytes in vivo, is required to avoid such adverse effects. Since the use of higher vertebrates is prohibited for medicinal and toxicological assays, we used zebrafish, whose melanocytes were regulated by mechanisms similar to mammals. Zebrafish larvae were treated with RD in breeding water for 3 days, which caused body lightening accompanied by a decrease in the number of melanophores. Interestingly, black particles were found at the bottom of culture dishes, suggesting that the melanophores peeled off from the body. In addition, RT-PCR analysis suggested that the mRNA levels of melanophore-specific genes were significantly low. An increase in the production of reactive oxygen species was found in larvae treated with RD. The treatments of the fish with other phenol compounds, which have been reported to cause leukoderma, also induced depigmentation and melanophore loss. These results suggest that zebrafish larvae could be used for the evaluation of leukoderma caused by chemicals, including RD.
Subject(s)
Butanols/adverse effects , Disease Models, Animal , Hypopigmentation , Zebrafish/metabolism , Animals , Butanols/pharmacology , Hypopigmentation/chemically induced , Hypopigmentation/metabolismSubject(s)
Butanols/adverse effects , Skin Pigmentation/drug effects , Skin/pathology , Vitiligo/chemically induced , Administration, Cutaneous , Adult , Aged , Aged, 80 and over , Antigens, CD/analysis , Antigens, CD/metabolism , Butanols/administration & dosage , Cadherins/analysis , Cadherins/metabolism , Case-Control Studies , Female , Glutamate-Cysteine Ligase/analysis , Glutamate-Cysteine Ligase/metabolism , Humans , Immunohistochemistry , Male , Melanocytes/drug effects , Melanocytes/metabolism , Middle Aged , Monophenol Monooxygenase/analysis , Monophenol Monooxygenase/antagonists & inhibitors , Monophenol Monooxygenase/metabolism , Skin/cytology , Skin/drug effects , Vitiligo/pathology , Young AdultABSTRACT
The ability of microorganisms to produce biofuels by fermentation is adversely affected by the perturbing effects of the hydrophobic biofuel on plasma membrane structure. It is demonstrated here that heterologous expression of metazoan, calcium-dependent, membrane-binding proteins of the annexin class can reduce deleterious effects of isobutanol on Saccharomyces cerevisiae viability and complex membrane functions. Therefore, expression of annexins in industrial strains of yeast or bacteria may prove beneficial in biofuel production.
Subject(s)
Biofuels/adverse effects , Butanols/adverse effects , Cell Membrane/drug effects , Fermentation , Saccharomyces cerevisiae/drug effects , Annexin A1/genetics , Annexin A5/genetics , Annexin A6/genetics , Calcium/metabolism , Humans , Industrial Microbiology , Lipids/chemistry , Metabolic EngineeringSubject(s)
Bimatoprost/administration & dosage , Butanols/adverse effects , Cosmetics/adverse effects , Dermatologic Agents/administration & dosage , Hypopigmentation/drug therapy , Skin Pigmentation/drug effects , Administration, Cutaneous , Adult , Drug Administration Schedule , Female , Humans , Hypopigmentation/chemically induced , Hypopigmentation/diagnosis , Hypopigmentation/physiopathology , Treatment OutcomeSubject(s)
Autoantibodies/blood , Butanols/adverse effects , Hypopigmentation/immunology , Skin Lightening Preparations/adverse effects , Vitiligo/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Autoantibodies/immunology , Child, Preschool , Female , Humans , Hypopigmentation/blood , Hypopigmentation/chemically induced , Male , Middle Aged , Vitiligo/blood , Young AdultABSTRACT
Saccharomyces cerevisiae genetically engineered to enhance butanol production will be used in a manufacturing process similar to that of fuel ethanol production, including co-production of distillers products for animal feed. A poultry feeding trial was conducted with simulated isobutanol-derived dried distillers grains with solubles (bDDGS), comprising non-fermentable corn solids and heat-inactivated Butamax modified yeast (BMY), to determine potential health effects. Simulated dried distillers grains were produced in 2 variants: bDDGS containing 10% (B10) or 50% (B50) BMY. The BMY concentrations were selected based on a conservative estimate from ethanol-derived distillers grains (eDDGS) approximating 2.5 and 12-fold margins of exposure. The B10 and B50 DDGS were evaluated in a 42-day feeding trial using male Ross 708 broiler chickens fed diets containing eDDGS, B50 DDGS, or B10 DDGS without or with isobutanol, 2,3-butanediol, and isobutyric acid metabolites each at target concentrations of 2 (B10-2), 5 (B10-5), or 10 (B10-10) times the anticipated specification limit in the commercial product. Diets were fed (n = 50 broilers/treatment) in 3 phases: starter phase with 8% DDGS and grower and finisher phases each with 15% DDGS. No statistically significant differences or diet-related effects on mortality, clinical pathology, or organ weights, and no microscopic observations associated with consumption of diets containing B10, B50, or B10 supplemented with metabolites at any targeted exposure level were observed. A lower (P < 0.05) mean absolute bursa of Fabricius weight in the B10-10 group compared to the B10 group was considered to be within the range of biological variability. A non-significant trend toward lower weight, gains, and feed intake, and higher feed:gain ratio was observed in the B10-10 group, and was considered a non-adverse palatability effect of consuming high concentrations of metabolites. These results demonstrate that consumption of phase diets containing simulated DDGS from a novel isobutanol production process was well-tolerated.
Subject(s)
Animal Feed/analysis , Butanols/administration & dosage , Animal Feed/adverse effects , Animal Nutritional Physiological Phenomena , Animals , Biofuels , Butanols/adverse effects , Butanols/metabolism , Chickens/growth & development , Distillation/methods , Edible Grain/chemistry , Fermentation , Genetic Engineering , Male , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , SafetyABSTRACT
BACKGROUND: Rhododendrol (rhododenol), an inhibitor of tyrosinase activity, is used as a skin-whitening component. Many cases of leukoderma after the application have been reported, termed rhododenol-induced leukoderma (RIL). The aim of this study was to clarify the pathogenesis of RIL morphologically through comparison with vitiligo. METHODS: We examined 14 cases of RIL and 15 cases of vitiligo using routine histopathology and immunohistochemistry. Thirteen cases of RIL, six cases of vitiligo and specimens of the RIL mouse model were evaluated by electron microscopy. RESULTS: There were common findings in RIL and vitiligo at the light-microscopic level: (a) vacuolar changes in the dermo-epidermal junction, (b) melanophages in the papillary dermis, (c) perifollicular lymphocyte infiltration, (d) loss or decrease of basal melanin pigment and (e) decrease of melanocytes in the lesions. The ultrastructural observations showed specific findings of RIL: (a) remaining melanocytes in depigmented lesions, (b) inhomogeneous melanization in melanocytes and (c) degenerated melanosomes in melanocytes. Some of the findings were observed in a RIL mouse model. Furthermore, it is notable that cell organelles of melanocytes were intact in our RIL cases. CONCLUSION: Morphological changes of RIL targeting melanosomes in melanocytes without degeneration of organelles reflect the reversible clinical course of most cases.
Subject(s)
Butanols/adverse effects , Melanocytes , Nevus , Skin Neoplasms , Vitiligo/drug therapy , Adult , Aged , Aged, 80 and over , Animals , Butanols/administration & dosage , Female , Humans , Melanocytes/metabolism , Melanocytes/pathology , Mice , Middle Aged , Neoplasms, Experimental/chemically induced , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , Nevus/chemically induced , Nevus/metabolism , Nevus/pathology , Skin Neoplasms/chemically induced , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Vitiligo/metabolism , Vitiligo/pathologyABSTRACT
Rhododendrol (RD), 4-(4-hydroxyphenyl)-2-butanol, inhibits melanin synthesis and had been used in skin-whitening cosmetic products until 2013. However, some individuals developed leukoderma on the skin where RD had been applied and have suffered from refractory depigmentation even after discontinuing RD application. Bimatoprost is a prostaglandin F2α analog and is often used for eyelash growth for cosmetic reasons as well as in the treatment of glaucoma. It was reported that bimatoprost induced skin pigmentation in addition to iris pigmentation as adverse effects. Therefore, we conducted an open-label single-center pilot study to evaluate the effectiveness of bimatoprost on refractory RD-induced leukoderma. Eleven Japanese female patients with skin type III who developed leukoderma on the exact or slightly extended area of skin where RD had been applied and gained a halt of enlargement of leukoderma or repigmentation on a part of the affected skin after discontinuation of RD were enrolled. Bimatoprost 0.03% solution was applied on the leukoderma once daily for 3 months, and then the frequency of application was increased to twice daily for the subsequent 3 months. Ten patients completed the 6-month course of bimatoprost application. In four patients, bimatoprost application brought slight improvement in RD-induced refractory leukoderma by dermatologists' evaluation. Because the number of enrolled patients was limited, further larger studies are necessary to better assess the effectiveness of bimatoprost in inducing repigmentation in patients with RD-induced refractory leukoderma.
Subject(s)
Bimatoprost/therapeutic use , Butanols/adverse effects , Hypopigmentation/drug therapy , Skin Lightening Preparations/adverse effects , Administration, Cutaneous , Adult , Aged , Bimatoprost/pharmacology , Drug Resistance , Female , Humans , Hypopigmentation/chemically induced , Hypopigmentation/pathology , Japan , Melanocytes/drug effects , Middle Aged , Pilot Projects , Skin/cytology , Skin/drug effects , Skin/pathology , Skin Pigmentation/drug effects , Treatment OutcomeABSTRACT
Rhododendrol (RD), 4-(4-hydroxyphenyl)-2-butanol, inhibits melanin synthesis and has been used for skin-whitening cosmetic products. RD has been very effective in lightening skin pigmentation, but some persons have developed so-called RD vitiligo, in which vitiligo starts on the face, neck and hands where topical RD has been applied and even extended over skin areas where RD has not been applied. RD vitiligo lesions in some patients have lasted for years and have been resistant to conventional vitiligo treatments. We examined the effects of cholecalciferol on RD vitiligo in a blinded randomized clinical trial. Forty-eight female RD vitiligo patients were recruited for the trial and were randomized into two groups: the vitamin D (VD)-intervention group that received daily 5000 IU cholecalciferol for 5 months and the control group. Three blinded investigators scored vitiligo improvement by comparing photographic images of baseline and at 5-month observation. Serum 25(OH)D3 of RD vitiligo patients was not significantly different from age-matched healthy volunteers. Twenty-two in the VD-intervention group and 23 in the control group completed the 5-month observation. Serum 25(OH)D3 levels were significantly increased after the 5-month VD intervention, while the control group did not change. The improvement scores were significantly higher in the VD-intervention group than the control group. The improvement scores were positively correlated with the serum 25(OH)D3 levels after the 5-month intervention period but not before the treatment. This blinded randomized clinical trial showed favor in administrating 5000 IU cholecalciferol daily to RD vitiligo patients.
Subject(s)
Butanols/adverse effects , Cholecalciferol/therapeutic use , Skin Lightening Preparations/adverse effects , Vitamins/therapeutic use , Vitiligo/drug therapy , Administration, Oral , Adult , Aged , Calcifediol/blood , Female , Humans , Middle Aged , Photography , Skin/diagnostic imaging , Skin/drug effects , Treatment Outcome , Vitiligo/blood , Vitiligo/chemically induced , Vitiligo/diagnostic imagingSubject(s)
Butanols/adverse effects , Drug Eruptions/etiology , Drug Eruptions/pathology , Hypopigmentation/chemically induced , Hypopigmentation/pathology , Stem Cells/drug effects , Adult , Aged , Cosmetics/adverse effects , Female , Humans , Japan , Middle Aged , Skin Lightening Preparations/adverse effectsABSTRACT
Rhododendrol-induced leukoderma is an acquired depigmentation that develops mainly at the contact site after repeated use of skin-whitening cosmetics containing rhododendrol. In most cases, cessation of further depigmentation or occurrence of repigmentation is observed after discontinuing the use of cosmetics. However, some patients develop vitiligo vulgaris through the spread of depigmentation into the non-exposed areas. Our study aims to investigate the patient-specific factors that may affect the extent of depigmentation or repigmentation, as well as development of vitiligo vulgaris. The degree of depigmentation of the face, neck and hands where exposed to rhododendrol was scored using photographs over time. The relationships between depigmentation score at first visit/improvement rate of depigmentation score and patient demographics were evaluated and three important clinical observations were made. First, repigmentation of the face was superior compared with that of the hands and neck, suggesting a possible role for the migration and differentiation of melanocyte stem cells from hair follicles, as a mechanism of repigmentation. Second, the intensity of rhododendrol exposure did not contribute to differences in the severity of depigmentation. This suggested a possibility of underlying genetic susceptibility to melanocyte cytotoxicity or immune reaction. Third, depigmentation score at first visit and past history of atopic dermatitis were significantly high in patients who developed vitiligo vulgaris. This suggested that severe chemical damage of melanocytes by rhododendrol leads to a higher risk of developing vitiligo vulgaris through the possible involvement of an immune reaction. These clinical observations may help to further understand the pathogenesis of rhododendrol-induced leukoderma.
Subject(s)
Butanols/adverse effects , Skin Diseases/chemically induced , Skin Pigmentation/drug effects , Adult , Aged , Aged, 80 and over , Female , Humans , Japan/epidemiology , Male , Middle Aged , Retrospective Studies , Skin Diseases/epidemiology , Young AdultABSTRACT
Rhododendrol is a phenolic compound that shows a tyrosinase-dependent toxicity for melanocytes and occasionally induces a vitiligo-like skin depigmentation. The post-tyrosinase mechanisms determining melanocyte death or survival, however, are far from clear. Here, we find that rhododendrol treatment leads to a reduction in the levels of cellular glutathione but also induces a cellular antioxidant response that eventually increases glutathione levels. We further find that rhododendrol toxicity is enhanced when glutathione levels are experimentally reduced and alleviated when glutathione levels are increased. Hence, it appears that the size of the preexisting glutathione pool along with the capacity to supply glutathione via the antioxidant response determines whether melanocytes survive or die after rhododendrol exposure. It is conceivable, therefore, that rhododendrol-induced leukoderma depends on the capacity to maintain appropriate glutathione levels and that enhancement of glutathione levels may preserve a patient's melanocytes and potentially help in repigmentation.
Subject(s)
Butanols/adverse effects , Glutathione/metabolism , Hypopigmentation/prevention & control , Melanocytes/cytology , Protective Agents/metabolism , Cell Survival , Cells, Cultured , Humans , Hypopigmentation/chemically induced , Hypopigmentation/metabolism , Melanocytes/drug effects , Melanocytes/metabolismSubject(s)
Butanols/adverse effects , Dermatitis, Contact/metabolism , Melanocytes/drug effects , Monophenol Monooxygenase/metabolism , NF-kappa B p50 Subunit/metabolism , Skin Lightening Preparations/adverse effects , Butanols/pharmacology , Cells, Cultured , Dermatitis, Contact/etiology , Humans , NF-kappa B p50 Subunit/antagonists & inhibitors , Skin Lightening Preparations/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Vitiligo/chemically induced , Vitiligo/metabolismABSTRACT
BACKGROUND: Many users in Japan of skin brightening/lightening cosmetics containing rhododendrol (RD) have developed leucoderma. Leucoderma appears on skin areas repeatedly treated with RD-containing cosmetics. RD-induced leucoderma (RDIL) presents different degrees of well-defined hypopigmentation. It is crucial to determine the degree of hypopigmentation to differentiate RDIL from vitiligo vulgaris (VV). OBJECTIVES: To quantitatively evaluate hypopigmentation of RDIL lesions and the recovery of pigmentation, and to compare the hypopigmentation with VV and normal skin. MATERIALS AND METHODS: Sixteen cases of RDIL, nine cases of VV and 15 healthy controls were examined using a novel multispectral camera (MSC) that can simultaneously obtain the reflection intensity at 10-nm wavelength intervals from 400 to 760 nm of the photographed area. ∆Absorbance was calculated by subtracting the log of reflection intensity of the target area from that of a white reflection standard. RESULTS: Most RDIL lesions showed lower ∆Absorbance than healthy skin and higher ∆Absorbance than VV lesions between 400 and 550 nm. Statistical comparison of the maximum ∆Absorbance from 420 to 460 nm (Max∆Absorbance) for VV, RDIL and control skin showed that the Max∆Absorbance of RDIL was significantly higher than that of VV and lower than that of control skin. The comparison of ∆Absorbance of the same sites in RDIL lesions between the initial visit and 6 months later showed significant improvement after 6 months. CONCLUSIONS: These studies demonstrated quantitative changes in RDIL and its recovery phase and suggested the utility of a MSC in obtaining objective colour information of skin disorders.